Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-30
2011-08-30
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
08008449
ABSTRACT:
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
REFERENCES:
patent: 5629204 (1997-05-01), Honjo et al.
patent: 5698520 (1997-12-01), Honjo et al.
patent: 5897862 (1999-04-01), Hardy et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 6632976 (2003-10-01), Tomizuka et al.
patent: 6803192 (2004-10-01), Chen
patent: 6808710 (2004-10-01), Wood et al.
patent: 6936704 (2005-08-01), Freeman et al.
patent: 7029674 (2006-04-01), Carreno et al.
patent: 7041474 (2006-05-01), Kingsbury
patent: 7101550 (2006-09-01), Wood et al.
patent: 7105328 (2006-09-01), Wood et al.
patent: 7122372 (2006-10-01), Hardy et al.
patent: 7329639 (2008-02-01), Hardy et al.
patent: 7332582 (2008-02-01), Hardy et al.
patent: 7488802 (2009-02-01), Collins et al.
patent: 2003/0232323 (2003-12-01), Freeman et al.
patent: 2004/0073957 (2004-04-01), Tomizuka et al.
patent: 2007/0065427 (2007-03-01), Freeman et al.
patent: 2007/0202100 (2007-08-01), Wood et al.
patent: 2008/0025979 (2008-01-01), Honjo et al.
patent: 0742795 (1998-09-01), None
patent: 1537878 (2005-06-01), None
patent: 07291996 (1998-11-01), None
patent: WO/97/07671 (1997-03-01), None
patent: WO 01/14557 (2001-03-01), None
patent: WO 02/079499 (2002-10-01), None
patent: WO 2003/006636 (2003-01-01), None
patent: WO 03/033644 (2003-04-01), None
patent: WO 03/042402 (2003-05-01), None
patent: WO 2004/056875 (2004-07-01), None
patent: WO 2004/072286 (2004-08-01), None
patent: WO 2006/021955 (2006-03-01), None
Rudikoff et al. 1982, Proc. Natl. Acad. Sci. USA, , 79: 1979-1983.
Panka et al., 1988, Proc. Natl. Acad. Sci. USA, 85: 3080-3084.
Wong RM et al., “Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs,”Int Immunol. (2007), 19(10):1223-34.
Berger et al., “Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies,”Clin Cancer Res. (2008); 14(10):3044-51.
Blank et al., “PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+T Cells”;Cancer Research; (2004); 64:1140-1145.
Cox et al., “A directory of human germ-line Vκsegments reveals a strong bias in their Usage”;Eur. J. Immunol.; (1994); 24:827-836.
Koga et al., “Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts”;Arterioscler. Thromb. Vasc. Biol.; (2004); 24(11):2057-2062.
Tomlinson et al., “The Repertoire of Human Germline VHSequences Reveals about Fifty Groups of VHSegments with Different Hypervariable Loops”;J. Mol. Biol.; (1992); 227:776-798.
Agata, et al., 1996, “Expression of the PD-1 antigen on the surface of stimulation mouse T and B lymphocytes,”Int Immunol, vol. 8: p. 765-772.
Bennett, et al., 2003, “Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses,”J Immunol, vol. 170: p. 711-718.
Blank, et al., 2005, “Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy,”Cancer Immunol. Immunother., vol. 54: p. 307-314.
Brown, et al., 2003, “Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production,”J. Immunol., vol. 170: p. 1257-1266.
Carter, et al., 2002, “PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2,”Eur J Immunol, vol. 32: p. 634-643.
Dong, et al., 2002, “Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion,”Nat Med., vol. 8: p. 783-800.
Dong, H. and Chen, L., 2003, “B7-H1 pathway and its role in the evasion of tumor immunity,”J Mol Med, vol. 81: p. 281-287.
Finger, et al., 1997, “The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors,” Gene, vol. 197: p. 177-187.
Freeman, et al., 2000, “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation,”J Exp Med, vol. 192: p. 1027-1034.
Hansen, et al., 1980, “Monoclonal Antibodies Identifying a Novel T-Cell Antigen and Ia Antigens of Human Lymphocytes,”Immunogenics, vol. 10: p. 247-260.
He, et al., 2004, “Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine,”J. Immunol., vol. 173: p. 4919-4928.
Hutloff, et al., 1999, “ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,”Nature, vol. 397: p. 263-266.
Ishida, et al., 1992, “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,”EMBO J., vol. 11: p. 3887-3895.
Iwai, et al., 2002, “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,”Proc. Nat'l. Acad. Sci. USA, vol. 99: p. 12293-12297.
Iwai, et al., 2002, “Microanatomical localization of PD-1 in human tonsils,”Immunology Letters, vol. 83, No. 3: p. 215-220.
Iwai, et al., 2005, “PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells,”Int. Immunol., vol. 17: p. 133-144.
Konishi, et al., 2004, “B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression,”Clin. Cancer Res., vol. 10: p. 5094-5100.
Latchman, et al., 2001, “PD-L2 is a second ligand for PD-1 and inhibits T cell activation,”Nat Immunol, vol. 2: p. 261-268.
Lonberg, et al., 1994, “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,”Nature, vol. 368, No. 6474: p. 856-859.
Nielsen, et al., 2004, “A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients,”Lupus, vol. 13: p. 510-516.
Nishimura, et al., 1999, “Development of Lupus-like Autoimmune Disease by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor,”Immunity, vol. 11: p. 141-151.
Nishimura, et al., 2001, “Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice,”Science, vol. 291: p. 319-322.
Okazaki, et al., 2001, “PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tryosine phosphatase 2 to phosphotyrosine,”PNAS, vol. 98: p. 13866-13871.
Okazaki, et al., 2002, “New regulatory co-receptors: inducible co-stimulator and PD-1,”Curr. Opin. Immunol., vol. 41, No. 6: p. 779-782.
Prokunina, L. and Alarcon-Riquelme, M., 2004, “The genetic basis of systemic lupus erythematosus-know
Cardarelli Josephine M.
Chen Bingliana
Korman Alan J.
Selby Mark J.
Srinivasan Mohan
Baker & Botts L.L.P.
Medarex Inc.
Ono Pharmaceutical Co. Ltd.
Ouspenski Ilia
LandOfFree
Human monoclonal antibodies to programmed death 1 (PD-1) and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human monoclonal antibodies to programmed death 1 (PD-1) and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies to programmed death 1 (PD-1) and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2697767